地高辛与酒石酸美托洛尔联合治疗心房纤颤的临床效果及安全性评价

The Clinical Efficacy and Safety of Digoxin and Metoprolol Tartrate in Treatment of Atrial Fibrillation

目的观察地高辛与酒石酸美托洛尔(倍他乐克)联合治疗心房纤颤的临床效果及安全性。方法将76例符合入选标准的心房纤颤患者随机分为观察组和对照组,分别采用地高辛与倍他乐克联合治疗和单纯地高辛治疗,比较治疗效果和不良发应。结果治疗3个月后,观察组治疗后静息时心室率和活动后心室率控制效果比对照组更好,差异有统计学意义(P<0.05)。观察组总有效率(94.7%)高于对照组(71.1%)(P<0.05)。两组均无明显不良反应。结论倍他乐克和地高辛联合应用治疗心房纤颤,临床疗效肯定,不良反应少,安全性高。

Objective To observe clinical effect and safety of digoxin and betaloc in treatment of atrial fibrillation.Methods 76 patients met the inclusion criteria for patients with atrial ifbrillation were divided into observation group and control group.ResultsAfter 3 months of treatment, the patients in the observation group resting ventricular rate and activities of ventricular rate control effect is better than the control group, the difference was statistically significant （P〈0.05）.Conclusion Betaloc and digoxin combination in the treatment of atrial ifbrillation, clinical efifcacy, is worthy of clinical application.